Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
Simcere Zaiming and AbbVie (ABBV) have announced a partnership to develop SIM0500, a novel trispecific antibody candidate for multiple myeloma treatment. The drug, currently in Phase 1 clinical trials in China and the U.S., targets GPRC5D, BCMA, and CD3 proteins.
The agreement includes an upfront payment from AbbVie to Simcere Zaiming, with potential milestone payments reaching up to $1.055 billion, plus tiered royalties on net sales outside Greater China. AbbVie will receive tiered royalties on sales within Greater China.
SIM0500, developed using Simcere Zaiming's T-cell engager polyspecific antibody technology platform, has demonstrated strong T cell cytotoxicity against multiple myeloma cells through various antitumor effects.
Simcere Zaiming e AbbVie (ABBV) hanno annunciato una partnership per sviluppare SIM0500, un nuovo candidato anticorpale trispecifico per il trattamento del mieloma multiplo. Il farmaco, attualmente in fase 1 di sperimentazione clinica in Cina e negli Stati Uniti, mira a bersagliare le proteine GPRC5D, BCMA e CD3.
L'accordo prevede un pagamento iniziale da parte di AbbVie a Simcere Zaiming, con potenziali pagamenti per traguardi che potrebbero raggiungere fino a 1,055 miliardi di dollari, oltre a royalties scaglionate sulle vendite nette al di fuori della Grande Cina. AbbVie riceverà royalties scaglionate sulle vendite all'interno della Grande Cina.
SIM0500, sviluppato utilizzando la piattaforma tecnologica degli anticorpi poliespecifici che ingaggiano le cellule T di Simcere Zaiming, ha dimostrato una forte citotossicità delle cellule T contro le cellule del mieloma multiplo attraverso vari effetti antitumorali.
Simcere Zaiming y AbbVie (ABBV) han anunciado una asociación para desarrollar SIM0500, un nuevo candidato a anticuerpo trispecífico para el tratamiento del mieloma múltiple. El medicamento, actualmente en ensayos clínicos de Fase 1 en China y EE. UU., tiene como objetivo las proteínas GPRC5D, BCMA y CD3.
El acuerdo incluye un pago inicial de AbbVie a Simcere Zaiming, con pagos por hitos potenciales que podrían alcanzar hasta $1.055 mil millones, además de regalías escalonadas sobre las ventas netas fuera de la Gran China. AbbVie recibirá regalías escalonadas sobre las ventas dentro de la Gran China.
SIM0500, desarrollado utilizando la plataforma tecnológica de anticuerpos poliespecíficos que enganchan células T de Simcere Zaiming, ha demostrado una fuerte citotoxicidad de células T contra las células de mieloma múltiple a través de varios efectos antitumorales.
Simcere Zaiming와 AbbVie (ABBV)가 다발성 골수종 치료를 위한 새로운 트리특이적 항체 후보인 SIM0500을 개발하기 위해 파트너십을 맺었다고 발표했습니다. 현재 중국과 미국에서 1상 임상 시험 중인 이 약물은 GPRC5D, BCMA 및 CD3 단백질을 표적으로 하고 있습니다.
이 계약에는 AbbVie가 Simcere Zaiming에 대한 초기 지불이 포함되어 있으며, 잠재적인 이정표 지급금이 최대 $1.055 billion까지 이를 수 있으며, 중국 본토 외부의 순매출에 대한 단계적 로열티가 포함됩니다. AbbVie는 중국 본토 내 판매에 대한 단계적 로열티를 받게 됩니다.
SIM0500은 Simcere Zaiming의 T세포 결합 다중 특정 항체 기술 플랫폼을 사용하여 개발되었으며, 여러 항종양 효과를 통해 다발성 골수종 세포에 대한 강력한 T세포 세포독성을 입증하였습니다.
Simcere Zaiming et AbbVie (ABBV) ont annoncé un partenariat pour développer SIM0500, un nouveau candidat anticorps trispecifique pour le traitement du myélome multiple. Le médicament, actuellement en essais cliniques de phase 1 en Chine et aux États-Unis, cible les protéines GPRC5D, BCMA et CD3.
Le contrat inclut un paiement initial d'AbbVie à Simcere Zaiming, avec des paiements d'étapes potentiels atteignant jusqu'à 1,055 milliard de dollars, plus des redevances échelonnées sur les ventes nettes en dehors de la Grande Chine. AbbVie recevra des redevances échelonnées sur les ventes en Grande Chine.
SIM0500, développé en utilisant la plateforme technologique d'anticorps polyspecifiques de Simcere Zaiming, a démontré une forte cytotoxicité des cellules T contre les cellules de myélome multiple grâce à divers effets anticancéreux.
Simcere Zaiming und AbbVie (ABBV) haben eine Partnerschaft zur Entwicklung von SIM0500, einem neuartigen trispezifischen Antikandidaten zur Behandlung vonMultiplem Myelom, angekündigt. Das Medikament befindet sich derzeit in Phase-1-Studien in China und den USA und zielt auf die Proteine GPRC5D, BCMA und CD3 ab.
Die Vereinbarung umfasst eine Vorauszahlung von AbbVie an Simcere Zaiming, mit potenziellen Meilensteinzahlungen von bis zu 1,055 Milliarden Dollar sowie gestaffelten Lizenzgebühren auf Nettoumsätze außerhalb von Großchina. AbbVie wird gestaffelte Lizenzgebühren auf Verkäufe innerhalb von Großchina erhalten.
SIM0500, das mit der polyspezifischen Antikörper-Technologieplattform von Simcere Zaiming entwickelt wurde, hat eine starke zytotoxische Wirkung von T-Zellen gegen multiple Myelomzellen durch verschiedene antitumorale Effekte gezeigt.
- Partnership with major pharmaceutical company AbbVie expands market reach
- Potential milestone payments of up to $1.055B plus tiered royalties
- Drug candidate already in Phase 1 clinical trials in both U.S. and China markets
- Early-stage drug development carries significant clinical trial risks
- Revenue generation dependent on successful clinical trials and regulatory approvals
Insights
This partnership represents a strategic advancement in multiple myeloma treatment development. The trispecific antibody SIM0500 employs an innovative approach by simultaneously targeting GPRC5D, BCMA and CD3 - a sophisticated mechanism that could potentially overcome resistance issues common in current therapies. The deal structure, with
The technology's dual-targeting of GPRC5D and BCMA is particularly noteworthy, as it addresses two critical pathways in multiple myeloma cell survival. This approach could potentially result in improved efficacy compared to single-target therapies, while the low-affinity CD3 binding might optimize the safety profile by reducing cytokine release syndrome risks.
For simpler understanding: Imagine this drug as a highly sophisticated GPS system that can track cancer cells using multiple coordinates simultaneously, making it harder for cancer cells to hide or develop resistance to treatment.
This deal significantly strengthens AbbVie's position in hematologic oncology, complementing their existing portfolio while sharing development risks. The structured payment approach - upfront payment plus
The reciprocal royalty arrangement for Greater China market access demonstrates sophisticated deal-making that benefits both parties. This structure could provide AbbVie with meaningful revenue streams in the rapidly growing Chinese market while allowing Simcere to maintain a strong presence in their home territory.
In simple terms: Think of this deal as a well-balanced partnership where both companies share the risks and rewards across different markets, similar to a joint venture between a local expert and a global powerhouse.
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and binding sites for the two tumor antigens: G-Protein-coupled receptor class 5 member D (GPRC5D) and B-cell maturation antigen (BCMA). SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects.
"As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations," said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. "We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma"
"SIM0500 is developed via Simcere Zaiming's proprietary T-cell engager platform," said Renhong Tang, PhD, CEO of Simcere Zaiming. "We are excited to partner with AbbVie on this novel drug candidate and look forward to working together to advance the clinical development of SIM0500. "
Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of up to
About AbbVie in Oncology
At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie's Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
About Simcere Zaiming
Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in
View original content to download multimedia:https://www.prnewswire.com/news-releases/simcere-zaiming-and-abbvie-announce-partnership-to-develop-a-novel-trispecific-antibody-candidate-in-multiple-myeloma-302349251.html
SOURCE Simcere Zaiming
FAQ
What is the potential value of the AbbVie (ABBV) and Simcere Zaiming partnership?
What type of drug is SIM0500 and what does it target?
What is the current development stage of SIM0500?
How will the royalty structure work in the ABBV-Simcere partnership?
What technology platform was used to develop SIM0500?
